Trial Profile

Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fexapotide (Primary)
Indications Prostate cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Nymox Pharmaceutical Corporation

Most Recent Events

27 Dec 2023 According to a Nymox Pharmaceutical Corporation media release, the company hopes to have more news from this study for supporters during Q1 or Q2 of 2024
25 Jul 2023 Results presented in a Nymox Pharmaceutical Corporation media release.
24 Feb 2020 Results published in a Nymox Pharmaceutical Corporation media release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com